Schulich school of Medicine and Dentistry logo Urology Schulich School of Medicine & Dentistry

Clinical Trials - Prostate Cancer

Contact Information for all of the following trials:

Principal Investigator: Dr. Chin
Urology Clinical Trials: 519.685.8500 ext. 58448
Hospital: London Health Sciences Centre - Victoria Hospital

Prostate Cancer - Detection
Urinary PCA-3 Levels in Patients diagnosed with ASAP, PIN and Normal Tissue on Repeat Prostate Biopsy- Men with previous negative biopsy undergo urinary PCA-3 testing to decide whether to re-biopsy.

Localized Prostate Cancer - Early
Active Surveillance Magnetic Resonance Imaging (ASIST Trial)- A multi-centre, prospective, randomized phase III trial to determine if multi-parametric Magnetic Resonance Imaging (MRI) can improve selection of subjects eligible for active surveillance through better detection of clinically significant cancer.

Multi-modality Prostate Cancer Image-Guided Interventions (IGPC-2 Study)- Pre-operative multimodality imaging of men undergoing radical prostatectomy as treatment of choice for T1-T2 PCa, or repeat prostate biopsy as standard of care.

A Randomized Phase 3 Study of Neo-adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer (NCIC PRC 3).

Robotic Laparoscopic Radical Prostatectomy:  A pilot study to evaluate the role of RALRP in the management of localized prostate cancer.

Prostate Cancer - Recurrent
A multi-centre clinical study of the Sonablate(R)500 (SB-500) for the treatment of locally recurrent prostate cancer with HIFU (high intensity focused ultrasound).

Prostate Cancer - Non-metastatic
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy (Amgen 560).

Prostate Cancer - Metastatic
A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing Orteronel   (TAK- 700) plus Prednisone with Placebo plus Prednisone in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Tak 700).